Multimodality therapy for the treatment of muscle-invasive bladder cancer
- PMID: 11101096
Multimodality therapy for the treatment of muscle-invasive bladder cancer
Abstract
In the United States, local management of muscle-invasive bladder cancer largely remains radical cystectomy with urinary diversion. However, this approach is undergoing transition. Organ-preserving approaches using a combination of multiple modalities have been successfully applied to the management of several types of cancer and clearly play an important role in the management of muscle-invasive bladder cancer as well. Since the 1980s, several single and multi-institutional trials have confirmed that a combined modality organ-preserving approach (chemotherapy administered in conjunction with radiation) consistently confers equivalent overall survival compared with survival following radical cystectomy. These trials are very encouraging and allow organ preservation to be considered an appropriate therapeutic option for patients with muscle-invasive bladder cancer.
Similar articles
-
Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer.J Surg Oncol. 1996 Nov;63(3):201-8. doi: 10.1002/(SICI)1096-9098(199611)63:3<201::AID-JSO13>3.0.CO;2-7. J Surg Oncol. 1996. PMID: 8944067 Review.
-
Bladder preservation: optimizing radiotherapy and integrated treatment strategies.BJU Int. 2008 Nov;102(9 Pt B):1345-53. doi: 10.1111/j.1464-410X.2008.07981.x. BJU Int. 2008. PMID: 19035903 Review.
-
An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.J Urol. 1999 Aug;162(2):445-50; discussion 450-1. J Urol. 1999. PMID: 10411054 Review.
-
Overview of bladder cancer trials in the Radiation Therapy Oncology Group.Cancer. 2003 Apr 15;97(8 Suppl):2115-9. doi: 10.1002/cncr.11282. Cancer. 2003. PMID: 12673704 Review.
-
Organ-sparing strategies in the management of invasive bladder cancer.Expert Rev Anticancer Ther. 2009 Dec;9(12):1765-75. doi: 10.1586/era.09.151. Expert Rev Anticancer Ther. 2009. PMID: 19954288 Review.
Cited by
-
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.Jpn J Clin Oncol. 2023 Jan 6;53(1):16-25. doi: 10.1093/jjco/hyac155. Jpn J Clin Oncol. 2023. PMID: 36300304 Free PMC article. Clinical Trial.
-
Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.Neoplasia. 2005 Feb;7(2):171-9. doi: 10.1593/neo.04478. Neoplasia. 2005. PMID: 15802022 Free PMC article.
-
DDX39 acts as a suppressor of invasion for bladder cancer.Cancer Sci. 2012 Jul;103(7):1363-9. doi: 10.1111/j.1349-7006.2012.02298.x. Epub 2012 Jun 4. Cancer Sci. 2012. PMID: 22494014 Free PMC article.
-
Expression of transcription factors snail, slug, and twist in human bladder carcinoma.J Exp Clin Cancer Res. 2010 Sep 1;29(1):119. doi: 10.1186/1756-9966-29-119. J Exp Clin Cancer Res. 2010. PMID: 20809941 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical